ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Alphamab Oncology and Suzhou Zelgen Biopharmaceuticals side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

Alphamab OncologySuzhou Zelgen Biopharmaceuticals
studies on the registry4083
open to participants now1629
phase 3 studies under way54
reach primary completion within a year710
programswith a study of their own in two years85

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phaseAlphamab OncologySuzhou Zelgen Biopharmaceuticals
Phase 1

Alphamab Oncology: 5 of its 8 programs at phase 1

  1. aflutinibphase 1
  2. JSKN016HCphase 1
  3. JSKN021phase 1
  4. JSKN022phase 1
  5. JSKN027phase 1
63%
00%
Phase 200%

Suzhou Zelgen Biopharmaceuticals: 2 of its 5 programs at phase 2

  1. Anti-VEGF/TGF-beta Bispecific Antibody Fusion Protein ZGGS18phase 2
  2. tislelizumabphase 2
40%
Phase 3

Alphamab Oncology: 3 of its 8 programs at phase 3

  1. JSKN016phase 3
  2. JSKN033phase 3
  3. anbenitamab repodatecanphase 3
38%

Suzhou Zelgen Biopharmaceuticals: 3 of its 5 programs at phase 3

  1. nilvanstomigphase 3
  2. Alveltamigphase 3
  3. jaktinibphase 3
60%
Approved, new studies00%00%

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
Alphamab Oncology4 readouts · 1 phase 3·

Alphamab Oncology, Dec ’26: 2 programs whose next study reaches primary completion, 1 in phase 3

  1. anbenitamab repodatecanphase 3 · Dec 30 · NCT06751485
  2. JSKN033phase 3 · Dec 31 · NCT06770881
·····

Alphamab Oncology, Jun ’27: 1 program whose next study reaches primary completion

  1. JSKN016phase 3 · Jun 30 · NCT06942234
·

Alphamab Oncology, Aug ’27: 1 program whose next study reaches primary completion

  1. JSKN022phase 1 · Aug 31 · NCT07292402
··
Suzhou Zelgen Biopharmaceuticals4 readouts · 0 phase 3·

Suzhou Zelgen Biopharmaceuticals, Dec ’26: 1 program whose next study reaches primary completion

  1. Alveltamigphase 3 · Dec 0 · NCT06592638
·

Suzhou Zelgen Biopharmaceuticals, Feb ’27: 1 program whose next study reaches primary completion

  1. jaktinibphase 3 · Feb 0 · NCT07565597
·

Suzhou Zelgen Biopharmaceuticals, Apr ’27: 1 program whose next study reaches primary completion

  1. nilvanstomigphase 3 · Apr 0 · NCT06903377

Suzhou Zelgen Biopharmaceuticals, May ’27: 1 program whose next study reaches primary completion

  1. Anti-VEGF/TGF-beta Bispecific Antibody Fusion Protein ZGGS18phase 2 · May 0 · NCT06938880
·····
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 22, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

Alphamab Oncology

New programs 0

None

Reached a new phase 1

  • JSKN033phase 3 · Aug 25 · Uterine Cervical Neoplasms

Study stopped 0

None

Primary completion later 0

None

Suzhou Zelgen Biopharmaceuticals

New programs 0

None

Reached a new phase 1

Study stopped 0

None

Primary completion later 1

Where they overlap

Conditions where at least two of them have programs: 3 in all. A program counts in each condition its studies name most.

ConditionAlphamab OncologySuzhou Zelgen Biopharmaceuticals
Carcinoma, Non-Small-Cell Lungboth · compare here

Alphamab Oncology in Carcinoma, Non-Small-Cell Lung: 3 programs

  1. JSKN016phase 3
  2. JSKN033phase 3
  3. aflutinibphase 1

Their studies: Alphamab Oncology’s studies of Carcinoma, Non-Small-Cell Lung in search

Suzhou Zelgen Biopharmaceuticals in Carcinoma, Non-Small-Cell Lung: 2 programs

  1. nilvanstomigphase 3
  2. tislelizumabphase 2

Their studies: Suzhou Zelgen Biopharmaceuticals’ studies of Carcinoma, Non-Small-Cell Lung in search

Stomach Neoplasmsboth · compare here

Alphamab Oncology in Stomach Neoplasms: 1 program

  1. anbenitamab repodatecanphase 3

Their studies: Alphamab Oncology’s studies of Stomach Neoplasms in search

Suzhou Zelgen Biopharmaceuticals in Stomach Neoplasms: 1 program

  1. tislelizumabphase 2

Their studies: Suzhou Zelgen Biopharmaceuticals’ studies of Stomach Neoplasms in search

Uterine Cervical Neoplasmsboth · compare here

Alphamab Oncology in Uterine Cervical Neoplasms: 1 program

  1. JSKN033phase 3

Their studies: Alphamab Oncology’s studies of Uterine Cervical Neoplasms in search

Suzhou Zelgen Biopharmaceuticals in Uterine Cervical Neoplasms: 1 program

  1. nilvanstomigphase 3

Their studies: Suzhou Zelgen Biopharmaceuticals’ studies of Uterine Cervical Neoplasms in search

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

No gene two of them both target, among the programs whose target is known.

A target, or a pathogen for a vaccine, known for: Alphamab Oncology 4 of 8 · Suzhou Zelgen Biopharmaceuticals 5 of 5 programs (8 of them by rule). Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.